Glucagon - Xeris Pharmaceuticals

Drug Profile

Glucagon - Xeris Pharmaceuticals

Alternative Names: G-Pen; G-Pen Jr; G-Pen Mini; Glucagon infusion - Xeris; Injectable stable glucagon - Xeris; Xeris glucagon; XeriSol G-Pump

Latest Information Update: 12 Jul 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator XERIS Pharmaceuticals
  • Developer Xeris Pharmaceuticals
  • Class Antihypoglycaemics; Pancreatic hormones
  • Mechanism of Action Glucagon receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Hypoglycaemia
  • New Molecular Entity No

Highest Development Phases

  • Phase III Hypoglycaemia

Most Recent Events

  • 25 Jun 2018 Efficacy and adverse events data from two phase III trials in Hypoglycaemia released by Xeris Pharmaceuticals
  • 03 May 2018 Xeris Pharmaceuticals completes a pivotal phase IIIb trial for severe Hypoglycaemia in patients with diabetes in USA and Canada (NCT03439072)
  • 15 Mar 2018 Xeris Pharmaceuticals and Integrated Medical Development initiate a phase II trial for Hypoglycaemia in USA (SC, Infusion) (NCT03490942)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top